Comparative Pharmacology
Head-to-head clinical analysis: LYNAVOY versus NELARABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYNAVOY versus NELARABINE.
LYNAVOY vs NELARABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
None Documented
None Documented
Clinical Note
moderateNelarabine + Digoxin
"Nelarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNelarabine + Digitoxin
"Nelarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNelarabine + Deslanoside
"Nelarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNelarabine + Acetyldigitoxin
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 30–40 hours, supporting once-daily dosing. Steady-state is achieved within 2–3 weeks.
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Primarily via bile into feces (approximately 77% of total clearance as unchanged drug and metabolites); renal excretion accounts for about 15% (less than 1% unchanged). A small amount is excreted in urine as metabolites.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent